Identification

Name
Itraconazole
Accession Number
DB01167  (APRD00040)
Type
Small Molecule
Groups
Approved, Investigational
Description

One of the triazole antifungal agents that inhibits cytochrome P-450-dependent enzymes resulting in impairment of ergosterol synthesis. It has been used against histoplasmosis, blastomycosis, cryptococcal meningitis & aspergillosis. [PubChem]

Structure
Thumb
Synonyms
  • Itraconazol
  • Itraconazole
  • Itraconazolum
  • Itrizole (tn)
  • Oriconazole
  • Sporanox (tn)
External IDs
R51211
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ItraconazoleCapsule100 mg/1OralPatriot Pharmaceuticals2005-02-01Not applicableUs
ItraconazoleCapsule100 mg/1OralCarilion Materials Management2005-02-01Not applicableUs10147 1700 03 nlmimage10 e60e7363
OnmelTablet200 mg/1OralMerz Pharmaceuticals2012-11-012018-05-11Us
SporanoxCapsule100 mg/1Oralbryant ranch prepack1992-09-11Not applicableUs
SporanoxSolution10 mg/mLOralJanssen Pharmaceuticals1997-02-21Not applicableUs
SporanoxCapsule100 mg/1OralJanssen Pharmaceuticals1992-09-11Not applicableUs
SporanoxCapsule100 mgOralJanssen Pharmaceuticals1993-12-31Not applicableCanada
Sporanox Oral Solution 10mg/mlSolution10 mgOralJanssen Pharmaceuticals1997-07-28Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ItraconazoleCapsule100 mg/1OralCadila Pharnmaceuticals2018-03-06Not applicableUs
ItraconazoleCapsule100 mg/1OralAlembic Pharmaceuticals Limited2016-12-16Not applicableUs
ItraconazoleCapsule100 mg/1OralEon Labs, Inc.2004-05-28Not applicableUs00185 0550 30 nlmimage10 433ba1dd
ItraconazoleCapsule, coated pellets100 mg/1OralNorth Star Rx Llc2017-09-01Not applicableUs
ItraconazoleCapsule100 mg/1OralAccord Healthcare Limited2016-12-30Not applicableUs
ItraconazoleSolution10 mg/mLOralAmneal Pharmaceuticals2014-04-30Not applicableUs
ItraconazoleCapsule100 mg/1OralAmneal Pharmaceuticals2016-09-27Not applicableUs
ItraconazoleCapsule100 mg/1OralAmerincan Health Packaging2017-04-01Not applicableUs
ItraconazoleCapsule100 mg/1OralZydus Pharmaceuticals Usa, Inc.2018-03-06Not applicableUs
ItraconazoleCapsule100 mg/1OralAv Pak2018-03-23Not applicableUs
International/Other Brands
Itrizole / Oriconazole / Sporal
Categories
UNII
304NUG5GF4
CAS number
84625-61-6
Weight
Average: 705.633
Monoisotopic: 704.239307158
Chemical Formula
C35H38Cl2N8O4
InChI Key
VHVPQPYKVGDNFY-ZPGVKDDISA-N
InChI
InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1
IUPAC Name
1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one
SMILES
CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@H]2CO[C@@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1

Pharmacology

Indication

For the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: pulmonary and extrapulmonary blastomycosis, histoplasmosis, aspergillosis, and onychomycosis.

Associated Conditions
Pharmacodynamics

Itraconazole is an imidazole/triazole type antifungal agent. Itraconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14 α-demethylation via the inhibition of the enzyme cytochrome P450 14α-demethylase. This enzyme converts lanosterol to ergosterol, and is required in fungal cell wall synthesis. The subsequent loss of normal sterols correlates with the accumulation of 14 α-methyl sterols in fungi and may be partly responsible for the fungistatic activity of fluconazole. Mammalian cell demethylation is much less sensitive to fluconazole inhibition. Itraconazole exhibits in vitro activity against Cryptococcus neoformans and Candida spp. Fungistatic activity has also been demonstrated in normal and immunocompromised animal models for systemic and intracranial fungal infections due to Cryptococcus neoformans and for systemic infections due to Candida albicans.

Mechanism of action

Itraconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Itraconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis.

TargetActionsOrganism
ALanosterol 14-alpha demethylase
inhibitor
Human
ALanosterol 14-alpha demethylase
inhibitor
Yeast
Absorption

The absolute oral bioavailability of itraconazole is 55%, and is maximal when taken with a full meal.

Volume of distribution
  • 796 ± 185 L
Protein binding

99.8%

Metabolism

Itraconazole is extensively metabolized by the liver into a large number of metabolites, including hydroxyitraconazole, the major metabolite. The main metabolic pathways are oxidative scission of the dioxolane ring, aliphatic oxidation at the 1-methylpropyl substituent, N-dealkylation of this 1-methylpropyl substituent, oxidative degradation of the piperazine ring and triazolone scission.

Route of elimination

Itraconazole is metabolized predominately by the cytochrome P450 3A4 isoenzyme system (CYP3A4) in the liver, resulting in the formation of several metabolites, including hydroxyitraconazole, the major metabolite. Fecal excretion of the parent drug varies between 3-18% of the dose. Renal excretion of the parent drug is less than 0.03% of the dose. About 40% of the dose is excreted as inactive metabolites in the urine. No single excreted metabolite represents more than 5% of a dose.

Half life

21 hours

Clearance
  • 381 +/- 95 mL/minute [IV administration]
Toxicity

No significant lethality was observed when itraconazole was administered orally to mice and rats at dosage levels of 320 mg/kg or to dogs at 200 mg/kg.

Affected organisms
  • Fungi, yeast and protozoans
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Itraconazole.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Itraconazole.Experimental, Illicit
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Itraconazole.Experimental, Illicit
AbemaciclibThe risk or severity of adverse effects can be increased when Itraconazole is combined with Abemaciclib.Approved, Investigational
AbirateroneThe metabolism of Abiraterone can be decreased when combined with Itraconazole.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Itraconazole.Approved, Investigational
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Itraconazole.Approved
Acetyl sulfisoxazoleThe metabolism of Itraconazole can be decreased when combined with Acetyl sulfisoxazole.Approved, Vet Approved
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Itraconazole.Approved
AcetyldigoxinThe serum concentration of Acetyldigoxin can be increased when it is combined with Itraconazole.Experimental
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Itraconazole.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Itraconazole.Approved
AgmatineThe metabolism of Agmatine can be decreased when combined with Itraconazole.Experimental, Investigational
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Itraconazole.Approved, Vet Approved
AlclometasoneThe metabolism of Alclometasone can be decreased when combined with Itraconazole.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Itraconazole.Experimental, Investigational
AlfentanilThe metabolism of Alfentanil can be decreased when combined with Itraconazole.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Itraconazole.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be increased when it is combined with Itraconazole.Approved, Investigational
AllylestrenolThe metabolism of Allylestrenol can be decreased when combined with Itraconazole.Approved
AlmasilateThe serum concentration of Itraconazole can be decreased when it is combined with Almasilate.Approved, Experimental
AlmotriptanThe serum concentration of Almotriptan can be increased when it is combined with Itraconazole.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Itraconazole.Approved
AloglutamolThe serum concentration of Itraconazole can be decreased when it is combined with Aloglutamol.Approved
AlosetronThe serum concentration of Alosetron can be increased when it is combined with Itraconazole.Approved, Withdrawn
alpha-Tocopherol acetateThe metabolism of alpha-Tocopherol acetate can be decreased when combined with Itraconazole.Approved
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Itraconazole.Approved, Illicit, Investigational
AluminiumThe serum concentration of Itraconazole can be decreased when it is combined with Aluminium.Approved, Investigational
Aluminium acetoacetateThe serum concentration of Itraconazole can be decreased when it is combined with Aluminium acetoacetate.Experimental
Aluminium glycinateThe serum concentration of Itraconazole can be decreased when it is combined with Aluminium glycinate.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmbrisentanThe metabolism of Ambrisentan can be decreased when combined with Itraconazole.Approved, Investigational
AmbroxolThe metabolism of Ambroxol can be decreased when combined with Itraconazole.Approved, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Itraconazole.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Itraconazole.Approved, Withdrawn
AminophyllineThe metabolism of Aminophylline can be decreased when combined with Itraconazole.Approved
AmiodaroneThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Amiodarone.Approved, Investigational
AmitriptylineThe metabolism of Amitriptyline can be decreased when combined with Itraconazole.Approved
AmlodipineThe metabolism of Amlodipine can be decreased when combined with Itraconazole.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Itraconazole.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Itraconazole.Approved, Investigational
AmrinoneThe therapeutic efficacy of Itraconazole can be increased when used in combination with Amrinone.Approved
AnagrelideItraconazole may increase the QTc-prolonging activities of Anagrelide.Approved
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Itraconazole.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Itraconazole.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Itraconazole.Investigational
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Itraconazole.Approved, Investigational
ApalutamideThe serum concentration of Itraconazole can be decreased when it is combined with Apalutamide.Approved, Investigational
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Itraconazole.Approved
ApremilastThe metabolism of Apremilast can be decreased when combined with Itraconazole.Approved, Investigational
AprepitantThe serum concentration of Itraconazole can be increased when it is combined with Aprepitant.Approved, Investigational
AranidipineThe metabolism of Aranidipine can be decreased when combined with Itraconazole.Approved, Investigational
ArgatrobanThe metabolism of Argatroban can be decreased when combined with Itraconazole.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Itraconazole.Approved, Investigational
Arsenic trioxideItraconazole may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Itraconazole.Approved
AsenapineThe serum concentration of Itraconazole can be decreased when it is combined with Asenapine.Approved
AstemizoleThe serum concentration of Astemizole can be increased when it is combined with Itraconazole.Approved, Withdrawn
AsunaprevirThe serum concentration of Asunaprevir can be increased when it is combined with Itraconazole.Approved, Investigational, Withdrawn
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Itraconazole.Investigational
AtazanavirThe metabolism of Itraconazole can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Itraconazole can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe risk or severity of adverse effects can be increased when Itraconazole is combined with Atorvastatin.Approved
AvanafilThe serum concentration of Avanafil can be increased when it is combined with Itraconazole.Approved
AvatrombopagThe metabolism of Avatrombopag can be decreased when combined with Itraconazole.Approved, Investigational
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Itraconazole.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Itraconazole.Approved
AzelnidipineThe metabolism of Azelnidipine can be decreased when combined with Itraconazole.Approved, Investigational
AzimilideThe therapeutic efficacy of Itraconazole can be increased when used in combination with Azimilide.Investigational
AzithromycinThe metabolism of Azithromycin can be decreased when combined with Itraconazole.Approved
BanoxantroneThe metabolism of Banoxantrone can be decreased when combined with Itraconazole.Investigational
BaricitinibThe metabolism of Baricitinib can be decreased when combined with Itraconazole.Approved, Investigational
BarnidipineThe serum concentration of Barnidipine can be increased when it is combined with Itraconazole.Approved
Beclomethasone dipropionateThe metabolism of Beclomethasone dipropionate can be decreased when combined with Itraconazole.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be increased when it is combined with Itraconazole.Approved
BencyclaneThe metabolism of Bencyclane can be decreased when combined with Itraconazole.Experimental
BenidipineThe metabolism of Benidipine can be decreased when combined with Itraconazole.Approved, Investigational
BenzatropineThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Benzatropine.Approved
BenzphetamineThe metabolism of Benzphetamine can be decreased when combined with Itraconazole.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Itraconazole.Approved
BepridilThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Itraconazole.Approved, Vet Approved
BexaroteneThe metabolism of Bexarotene can be decreased when combined with Itraconazole.Approved, Investigational
BezafibrateThe metabolism of Bezafibrate can be decreased when combined with Itraconazole.Approved, Investigational
BicalutamideThe metabolism of Bicalutamide can be decreased when combined with Itraconazole.Approved
BictegravirThe metabolism of Bictegravir can be decreased when combined with Itraconazole.Approved, Investigational
BioallethrinThe metabolism of Bioallethrin can be decreased when combined with Itraconazole.Approved, Experimental
Bismuth subcitrate potassiumThe serum concentration of Itraconazole can be decreased when it is combined with Bismuth Subcitrate.Approved, Investigational
Bismuth subnitrateThe serum concentration of Itraconazole can be decreased when it is combined with Bismuth subnitrate.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Itraconazole.Approved
BlonanserinThe metabolism of Blonanserin can be decreased when combined with Itraconazole.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Itraconazole.Approved, Withdrawn
BortezomibThe serum concentration of Bortezomib can be increased when it is combined with Itraconazole.Approved, Investigational
BosentanThe serum concentration of Itraconazole can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Itraconazole.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Itraconazole.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Itraconazole.Approved, Investigational
BrigatinibThe serum concentration of Brigatinib can be increased when it is combined with Itraconazole.Approved, Investigational
BrinzolamideThe serum concentration of Brinzolamide can be increased when it is combined with Itraconazole.Approved
BrivaracetamThe metabolism of Brivaracetam can be decreased when combined with Itraconazole.Approved, Investigational
BromazepamThe metabolism of Bromazepam can be decreased when combined with Itraconazole.Approved, Illicit, Investigational
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Itraconazole.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Itraconazole.Approved
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Itraconazole.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Itraconazole.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Itraconazole.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Itraconazole.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Itraconazole.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Itraconazole.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Itraconazole.Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Itraconazole.Approved
CabozantinibThe serum concentration of Cabozantinib can be increased when it is combined with Itraconazole.Approved, Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Itraconazole.Approved
CalcitriolThe metabolism of Calcitriol can be decreased when combined with Itraconazole.Approved, Nutraceutical
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium silicateThe serum concentration of Itraconazole can be decreased when it is combined with Calcium silicate.Experimental
CanagliflozinThe metabolism of Canagliflozin can be decreased when combined with Itraconazole.Approved
CannabidiolThe metabolism of Cannabidiol can be decreased when combined with Itraconazole.Approved, Investigational
CarbamazepineThe serum concentration of Itraconazole can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Itraconazole.Approved
CarboxyamidotriazoleThe metabolism of Carboxyamidotriazole can be decreased when combined with Itraconazole.Investigational
CariprazineThe metabolism of Cariprazine can be decreased when combined with Itraconazole.Approved, Investigational
CaroverineThe metabolism of Caroverine can be decreased when combined with Itraconazole.Experimental
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Itraconazole.Approved, Investigational
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Itraconazole.Approved, Investigational
CeliprololThe metabolism of Celiprolol can be decreased when combined with Itraconazole.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Itraconazole.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Itraconazole.Approved, Withdrawn
CetirizineThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Itraconazole.Approved
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be decreased when combined with Itraconazole.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Itraconazole.Approved, Illicit, Investigational
ChloroquineThe metabolism of Chloroquine can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Chlorphenamine.Approved
ChlorpromazineThe metabolism of Chlorpromazine can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Itraconazole.Approved
CholecalciferolThe metabolism of Cholecalciferol can be decreased when combined with Itraconazole.Approved, Nutraceutical
CiclesonideThe metabolism of Ciclesonide can be decreased when combined with Itraconazole.Approved, Investigational
CilnidipineThe metabolism of Cilnidipine can be decreased when combined with Itraconazole.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Itraconazole.Approved, Investigational
CimetidineCimetidine can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CinacalcetThe metabolism of Cinacalcet can be decreased when combined with Itraconazole.Approved
CinnarizineThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Cinnarizine.Approved, Investigational
CiprofloxacinThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Ciprofloxacin.Approved, Investigational
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Itraconazole.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Citalopram can be decreased when combined with Itraconazole.Approved
ClarithromycinThe metabolism of Clarithromycin can be decreased when combined with Itraconazole.Approved
ClemastineThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Clemastine.Approved, Investigational
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Itraconazole.Approved, Investigational
ClindamycinThe metabolism of Clindamycin can be decreased when combined with Itraconazole.Approved, Vet Approved
ClobazamThe metabolism of Clobazam can be decreased when combined with Itraconazole.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Itraconazole.Approved, Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Itraconazole.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Itraconazole.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Itraconazole.Approved
ClofazimineThe metabolism of Clofazimine can be decreased when combined with Itraconazole.Approved, Investigational
ClofibrateThe metabolism of Clofibrate can be decreased when combined with Itraconazole.Approved, Investigational
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Itraconazole.Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
ClonazepamThe metabolism of Clonazepam can be decreased when combined with Itraconazole.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Itraconazole.Approved
ClopidogrelThe metabolism of Clopidogrel can be decreased when combined with Itraconazole.Approved
ClorazepateThe metabolism of Clorazepate can be decreased when combined with Itraconazole.Approved, Illicit
ClorindioneThe serum concentration of Clorindione can be increased when it is combined with Itraconazole.Experimental
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Itraconazole.Approved, Illicit
ClotrimazoleThe metabolism of Itraconazole can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Clozapine can be decreased when combined with Itraconazole.Approved
CobicistatThe serum concentration of Cobicistat can be increased when it is combined with Itraconazole.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Itraconazole.Approved, Investigational
CocaineThe metabolism of Cocaine can be decreased when combined with Itraconazole.Approved, Illicit
CodeineThe metabolism of Codeine can be decreased when combined with Itraconazole.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Itraconazole.Approved
ConivaptanThe serum concentration of Conivaptan can be increased when it is combined with Itraconazole.Approved, Investigational
Conjugated estrogensThe metabolism of Conjugated estrogens can be decreased when combined with Itraconazole.Approved
CopanlisibThe metabolism of Copanlisib can be decreased when combined with Itraconazole.Approved, Investigational
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Itraconazole.Investigational
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Itraconazole.Experimental
Cortisone acetateThe metabolism of Cortisone acetate can be decreased when combined with Itraconazole.Approved, Investigational
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Itraconazole.Approved
CurcuminThe metabolism of Itraconazole can be decreased when combined with Curcumin.Approved, Investigational
CyclandelateThe metabolism of Cyclandelate can be decreased when combined with Itraconazole.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Itraconazole.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Itraconazole.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
CymarinThe serum concentration of Cymarin can be increased when it is combined with Itraconazole.Experimental
CytarabineThe metabolism of Cytarabine can be decreased when combined with Itraconazole.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Itraconazole.Approved
DabrafenibThe serum concentration of Itraconazole can be decreased when it is combined with Dabrafenib.Approved, Investigational
DaclatasvirThe serum concentration of Daclatasvir can be increased when it is combined with Itraconazole.Approved, Investigational
DantroleneThe metabolism of Dantrolene can be decreased when combined with Itraconazole.Approved, Investigational
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Itraconazole.Approved
DapoxetineThe serum concentration of Dapoxetine can be increased when it is combined with Itraconazole.Investigational
DapsoneThe metabolism of Dapsone can be decreased when combined with Itraconazole.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Itraconazole.Approved, Investigational
DarodipineThe metabolism of Darodipine can be decreased when combined with Itraconazole.Experimental
DarunavirThe serum concentration of Itraconazole can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Itraconazole.Approved
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Itraconazole.Approved, Investigational
DaunorubicinThe metabolism of Daunorubicin can be decreased when combined with Itraconazole.Approved
DeferasiroxThe serum concentration of Itraconazole can be decreased when it is combined with Deferasirox.Approved, Investigational
DeflazacortThe metabolism of Deflazacort can be decreased when combined with Itraconazole.Approved, Investigational
DelamanidItraconazole may increase the QTc-prolonging activities of Delamanid.Approved, Investigational
DelavirdineThe metabolism of Delavirdine can be decreased when combined with Itraconazole.Approved
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Itraconazole.Approved
DesonideThe serum concentration of Desonide can be increased when it is combined with Itraconazole.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Itraconazole.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Itraconazole.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Itraconazole.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Desvenlafaxine can be decreased when combined with Itraconazole.Approved, Investigational
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Itraconazole.Approved, Investigational
DexamethasoneThe metabolism of Dexamethasone can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Itraconazole.Vet Approved
DexbrompheniramineThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Dexbrompheniramine.Approved
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Itraconazole.Approved
DexlansoprazoleThe serum concentration of Itraconazole can be decreased when it is combined with Dexlansoprazole.Approved, Investigational
DexniguldipineThe metabolism of Dexniguldipine can be decreased when combined with Itraconazole.Experimental
DexrabeprazoleThe serum concentration of Itraconazole can be decreased when it is combined with Dexrabeprazole.Experimental
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Itraconazole.Approved
DextropropoxypheneThe metabolism of Dextropropoxyphene can be decreased when combined with Itraconazole.Approved, Illicit, Investigational, Withdrawn
DexverapamilThe metabolism of Dexverapamil can be decreased when combined with Itraconazole.Experimental
DiazepamThe metabolism of Diazepam can be decreased when combined with Itraconazole.Approved, Illicit, Investigational, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Itraconazole.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Itraconazole.Approved
DidanosineDidanosine can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DienogestThe serum concentration of Dienogest can be increased when it is combined with Itraconazole.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Itraconazole.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Itraconazole.Approved, Investigational, Withdrawn
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Itraconazole.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Itraconazole.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Itraconazole.Approved
Digoxin Immune Fab (Ovine)The serum concentration of Digoxin Immune Fab (Ovine) can be increased when it is combined with Itraconazole.Approved
Dihydro-alpha-ergocryptineThe metabolism of Dihydro-alpha-ergocryptine can be decreased when combined with Itraconazole.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Itraconazole.Approved, Illicit
DihydroergocornineThe risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Itraconazole.Approved
DihydroergocristineThe risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Itraconazole.Approved, Experimental
DihydroergocryptineThe risk or severity of adverse effects can be increased when Dihydroergocryptine is combined with Itraconazole.Experimental
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Itraconazole.Approved, Investigational
DiltiazemThe metabolism of Diltiazem can be decreased when combined with Itraconazole.Approved, Investigational
DimenhydrinateThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Dimenhydrinate.Approved
DiphenadioneThe serum concentration of Diphenadione can be increased when it is combined with Itraconazole.Experimental
DiphenhydramineThe risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Itraconazole.Approved, Investigational
DisopyramideThe serum concentration of Disopyramide can be increased when it is combined with Itraconazole.Approved
DisulfiramThe metabolism of Disulfiram can be decreased when combined with Itraconazole.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Itraconazole.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be increased when it is combined with Itraconazole.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Itraconazole.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Itraconazole.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Itraconazole.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Itraconazole.Approved
DotarizineThe metabolism of Dotarizine can be decreased when combined with Itraconazole.Investigational
DoxazosinThe serum concentration of Itraconazole can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Itraconazole can be decreased when it is combined with Doxepin.Approved, Investigational
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Itraconazole.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Itraconazole.Approved, Investigational
DoxycyclineThe metabolism of Itraconazole can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Doxylamine.Approved, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Itraconazole.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be increased when it is combined with Itraconazole.Approved
DroperidolItraconazole may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be increased when it is combined with Itraconazole.Approved
DutasterideThe serum concentration of Dutasteride can be increased when it is combined with Itraconazole.Approved, Investigational
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Itraconazole.Approved
EfavirenzThe serum concentration of Itraconazole can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe metabolism of Efonidipine can be decreased when combined with Itraconazole.Approved, Investigational
ElbasvirThe metabolism of Elbasvir can be decreased when combined with Itraconazole.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Itraconazole.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Itraconazole.Approved
ElvitegravirThe serum concentration of Elvitegravir can be increased when it is combined with Itraconazole.Approved
EmopamilThe metabolism of Emopamil can be decreased when combined with Itraconazole.Experimental
EnalaprilThe metabolism of Enalapril can be decreased when combined with Itraconazole.Approved, Vet Approved
EnasidenibThe metabolism of Enasidenib can be decreased when combined with Itraconazole.Approved, Investigational
EnzalutamideThe serum concentration of Itraconazole can be decreased when it is combined with Enzalutamide.Approved
EperisoneThe metabolism of Eperisone can be decreased when combined with Itraconazole.Approved, Investigational
EpinastineThe serum concentration of Itraconazole can be decreased when it is combined with Epinastine.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be increased when it is combined with Itraconazole.Approved
EquileninThe serum concentration of Equilenin can be increased when it is combined with Itraconazole.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Itraconazole.Approved
ErgocalciferolThe metabolism of Ergocalciferol can be decreased when combined with Itraconazole.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Itraconazole.Approved
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Itraconazole.Approved
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Itraconazole.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Itraconazole.Approved, Investigational
ErythromycinThe metabolism of Erythromycin can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
EscitalopramThe metabolism of Escitalopram can be decreased when combined with Itraconazole.Approved, Investigational
EsomeprazoleThe serum concentration of Itraconazole can be decreased when it is combined with Esomeprazole.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be increased when it is combined with Itraconazole.Approved, Illicit
EstradiolThe metabolism of Estradiol can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
Estradiol acetateThe metabolism of Estradiol acetate can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
Estradiol benzoateThe metabolism of Estradiol benzoate can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
Estradiol cypionateThe metabolism of Estradiol cypionate can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
Estradiol dienanthateThe metabolism of Estradiol dienanthate can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
Estradiol valerateThe metabolism of Estradiol valerate can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
EstramustineThe metabolism of Estramustine can be decreased when combined with Itraconazole.Approved, Investigational
Estrogens, esterifiedThe metabolism of Estrogens, esterified can be decreased when combined with Itraconazole.Approved
EstroneThe metabolism of Estrone can be decreased when combined with Itraconazole.Approved
Estrone sulfateThe metabolism of Estrone sulfate can be decreased when combined with Itraconazole.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Itraconazole.Approved, Investigational
EthanolThe metabolism of Ethanol can be decreased when combined with Itraconazole.Approved
Ethinyl EstradiolThe metabolism of Ethinyl Estradiol can be decreased when combined with Itraconazole.Approved
EthosuximideThe metabolism of Ethosuximide can be decreased when combined with Itraconazole.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Itraconazole.Withdrawn
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Itraconazole.Approved, Illicit
EtizolamThe serum concentration of Etizolam can be increased when it is combined with Itraconazole.Approved
EtonogestrelThe metabolism of Etonogestrel can be decreased when combined with Itraconazole.Approved, Investigational
EtoposideThe metabolism of Etoposide can be decreased when combined with Itraconazole.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Itraconazole.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Itraconazole.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Itraconazole.Approved
ExemestaneThe metabolism of Exemestane can be decreased when combined with Itraconazole.Approved, Investigational
FamciclovirThe metabolism of Famciclovir can be decreased when combined with Itraconazole.Approved, Investigational
FamotidineFamotidine can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FelbamateThe metabolism of Felbamate can be decreased when combined with Itraconazole.Approved
FelodipineThe serum concentration of Felodipine can be increased when it is combined with Itraconazole.Approved, Investigational
FendilineThe metabolism of Fendiline can be decreased when combined with Itraconazole.Withdrawn
FenofibrateThe metabolism of Fenofibrate can be decreased when combined with Itraconazole.Approved
FentanylThe serum concentration of Fentanyl can be increased when it is combined with Itraconazole.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Itraconazole.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Itraconazole.Approved, Investigational
FinasterideThe metabolism of Finasteride can be decreased when combined with Itraconazole.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Itraconazole.Approved, Investigational
Fish oilThe metabolism of Fish oil can be decreased when combined with Itraconazole.Approved, Nutraceutical
FlecainideItraconazole may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Itraconazole.Approved, Investigational
FluasteroneThe serum concentration of Fluasterone can be increased when it is combined with Itraconazole.Investigational
FluconazoleThe metabolism of Itraconazole can be decreased when combined with Fluconazole.Approved, Investigational
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Itraconazole.Approved, Investigational
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Itraconazole.Approved, Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Itraconazole.Approved, Vet Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Itraconazole.Approved
FlunisolideThe metabolism of Flunisolide can be decreased when combined with Itraconazole.Approved, Investigational
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Itraconazole.Approved, Illicit
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Itraconazole.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Itraconazole.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Itraconazole.Approved, Withdrawn
FluorometholoneThe metabolism of Fluorometholone can be decreased when combined with Itraconazole.Approved, Investigational
FluoxetineThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Fluoxetine.Approved, Vet Approved
FlupentixolItraconazole may increase the QTc-prolonging activities of Flupentixol.Approved, Investigational, Withdrawn
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Itraconazole.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Itraconazole.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Itraconazole.Approved
FlurazepamThe metabolism of Flurazepam can be decreased when combined with Itraconazole.Approved, Illicit, Investigational
FluspirileneThe metabolism of Fluspirilene can be decreased when combined with Itraconazole.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Itraconazole.Approved, Investigational
FluticasoneThe serum concentration of Fluticasone can be increased when it is combined with Itraconazole.Approved, Experimental, Investigational
Fluticasone furoateThe metabolism of Fluticasone furoate can be decreased when combined with Itraconazole.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Itraconazole.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Itraconazole.Approved
FluvoxamineThe serum concentration of Itraconazole can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Itraconazole.Approved, Investigational, Withdrawn
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be increased when Fosamprenavir is used in combination with Itraconazole.Approved
FosaprepitantThe serum concentration of Itraconazole can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of hyperkalemia can be increased when Fosinopril is combined with Itraconazole.Approved
FosnetupitantThe metabolism of Fosnetupitant can be decreased when combined with Itraconazole.Approved
FosphenytoinThe serum concentration of Itraconazole can be decreased when it is combined with Fosphenytoin.Approved, Investigational
FostamatinibThe metabolism of Fostamatinib can be decreased when combined with Itraconazole.Approved, Investigational
FulvestrantThe metabolism of Fulvestrant can be decreased when combined with Itraconazole.Approved, Investigational
Fusidic AcidThe serum concentration of Itraconazole can be increased when it is combined with Fusidic Acid.Approved, Investigational
GabapentinThe metabolism of Gabapentin can be decreased when combined with Itraconazole.Approved, Investigational
Gadobenic acidItraconazole may increase the QTc-prolonging activities of Gadobenic acid.Approved, Investigational
GalantamineThe metabolism of Galantamine can be decreased when combined with Itraconazole.Approved
GallopamilThe metabolism of Gallopamil can be decreased when combined with Itraconazole.Investigational
GefitinibThe metabolism of Gefitinib can be decreased when combined with Itraconazole.Approved, Investigational
GemfibrozilThe metabolism of Gemfibrozil can be decreased when combined with Itraconazole.Approved
GemifloxacinItraconazole may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GitoformateThe serum concentration of Gitoformate can be increased when it is combined with Itraconazole.Experimental
GlipizideThe metabolism of Glipizide can be decreased when combined with Itraconazole.Approved, Investigational
GlyburideThe metabolism of Glyburide can be decreased when combined with Itraconazole.Approved
GlycerinThe serum concentration of Itraconazole can be increased when it is combined with Glycerin.Approved, Investigational
GoserelinItraconazole may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronThe metabolism of Granisetron can be decreased when combined with Itraconazole.Approved, Investigational
GrazoprevirThe metabolism of Grazoprevir can be decreased when combined with Itraconazole.Approved
GrepafloxacinThe metabolism of Grepafloxacin can be decreased when combined with Itraconazole.Approved, Investigational, Withdrawn
GuanfacineThe serum concentration of Guanfacine can be increased when it is combined with Itraconazole.Approved, Investigational
HalcinonideThe serum concentration of Halcinonide can be increased when it is combined with Itraconazole.Approved, Investigational, Withdrawn
HalofantrineThe serum concentration of Halofantrine can be increased when it is combined with Itraconazole.Approved
HaloperidolThe metabolism of Haloperidol can be decreased when combined with Itraconazole.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Itraconazole.Approved, Vet Approved
HE3286The serum concentration of HE3286 can be increased when it is combined with Itraconazole.Investigational
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Itraconazole.Approved
HistamineThe metabolism of Histamine can be decreased when combined with Itraconazole.Approved, Investigational
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Itraconazole.Approved, Illicit
HydrocortisoneThe metabolism of Hydrocortisone can be decreased when combined with Itraconazole.Approved, Vet Approved
Hydrocortisone acetateThe metabolism of Hydrocortisone acetate can be decreased when combined with Itraconazole.Approved, Vet Approved
Hydrocortisone butyrateThe metabolism of Hydrocortisone butyrate can be decreased when combined with Itraconazole.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Itraconazole.Approved, Illicit
HydrotalciteThe serum concentration of Itraconazole can be decreased when it is combined with Hydrotalcite.Approved, Experimental, Investigational
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be decreased when combined with Itraconazole.Approved, Investigational
HydroxyzineThe risk or severity of QTc prolongation can be increased when Hydroxyzine is combined with Itraconazole.Approved
IbandronateThe risk or severity of QTc prolongation can be increased when Ibandronate is combined with Itraconazole.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be increased when it is combined with Itraconazole.Approved
IbuprofenThe serum concentration of Itraconazole can be increased when it is combined with Ibuprofen.Approved
IbutilideItraconazole may increase the QTc-prolonging activities of Ibutilide.Approved
IcotinibThe metabolism of Icotinib can be decreased when combined with Itraconazole.Approved, Investigational
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Itraconazole.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Itraconazole resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Itraconazole.Approved
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Itraconazole.Approved
ImidafenacinThe serum concentration of Imidafenacin can be increased when it is combined with Itraconazole.Approved, Investigational
ImipramineThe metabolism of Imipramine can be decreased when combined with Itraconazole.Approved
ImiquimodThe metabolism of Imiquimod can be decreased when combined with Itraconazole.Approved, Investigational
IndacaterolThe metabolism of Indacaterol can be decreased when combined with Itraconazole.Approved
IndapamideThe metabolism of Indapamide can be decreased when combined with Itraconazole.Approved
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Itraconazole.Approved
IpecacThe metabolism of Ipecac can be decreased when combined with Itraconazole.Approved, Withdrawn
IpratropiumThe metabolism of Ipratropium can be decreased when combined with Itraconazole.Approved
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Itraconazole.Approved, Investigational
IsavuconazoleThe serum concentration of Isavuconazole can be increased when it is combined with Itraconazole.Approved, Investigational
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Itraconazole.Approved, Investigational
IsoniazidThe serum concentration of Itraconazole can be decreased when it is combined with Isoniazid.Approved, Investigational
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be decreased when combined with Itraconazole.Approved, Investigational
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be decreased when combined with Itraconazole.Approved
IsradipineThe metabolism of Isradipine can be decreased when combined with Itraconazole.Approved, Investigational
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Itraconazole.Investigational
IvabradineThe serum concentration of Ivabradine can be increased when it is combined with Itraconazole.Approved
IvacaftorThe serum concentration of Ivacaftor can be increased when it is combined with Itraconazole.Approved
IvermectinThe metabolism of Ivermectin can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be increased when it is combined with Itraconazole.Approved, Investigational
IxazomibThe metabolism of Ixazomib can be decreased when combined with Itraconazole.Approved, Investigational
KetamineThe metabolism of Ketamine can be decreased when combined with Itraconazole.Approved, Vet Approved
KetazolamThe metabolism of Ketazolam can be decreased when combined with Itraconazole.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Itraconazole.Approved, Investigational
KetoconazoleThe metabolism of Itraconazole can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of hyperkalemia can be increased when Itraconazole is combined with Labetalol.Approved
LacidipineThe serum concentration of Lacidipine can be increased when it is combined with Itraconazole.Approved, Investigational
LacosamideThe serum concentration of Lacosamide can be increased when it is combined with Itraconazole.Approved
LafutidineThe serum concentration of Itraconazole can be decreased when it is combined with Lafutidine.Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Itraconazole.Approved, Investigational
LamotrigineThe metabolism of Lamotrigine can be decreased when combined with Itraconazole.Approved, Investigational
Lanatoside CThe serum concentration of Lanatoside C can be increased when it is combined with Itraconazole.Experimental
LansoprazoleThe serum concentration of Itraconazole can be decreased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be increased when it is combined with Itraconazole.Approved, Investigational
LaquinimodThe metabolism of Laquinimod can be decreased when combined with Itraconazole.Investigational
LavoltidineThe serum concentration of Itraconazole can be decreased when it is combined with Lavoltidine.Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Itraconazole.Approved
LenvatinibThe metabolism of Lenvatinib can be decreased when combined with Itraconazole.Approved, Investigational
LercanidipineThe serum concentration of Lercanidipine can be increased when it is combined with Itraconazole.Approved, Investigational
LetrozoleThe metabolism of Letrozole can be decreased when combined with Itraconazole.Approved, Investigational
LeuprolideItraconazole may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamThe metabolism of Levetiracetam can be decreased when combined with Itraconazole.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be increased when it is combined with Itraconazole.Approved, Investigational
LevocetirizineThe metabolism of Levocetirizine can be decreased when combined with Itraconazole.Approved
LevofloxacinItraconazole may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe metabolism of Levomethadyl Acetate can be decreased when combined with Itraconazole.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Itraconazole.Approved, Investigational
LevonorgestrelThe metabolism of Levonorgestrel can be decreased when combined with Itraconazole.Approved, Investigational
LevothyroxineThe metabolism of Levothyroxine can be decreased when combined with Itraconazole.Approved
LidocaineThe metabolism of Lidocaine can be decreased when combined with Itraconazole.Approved, Vet Approved
LidoflazineThe metabolism of Lidoflazine can be decreased when combined with Itraconazole.Experimental
LisurideThe risk or severity of adverse effects can be increased when Lisuride is combined with Itraconazole.Approved, Investigational
LomerizineThe metabolism of Lomerizine can be decreased when combined with Itraconazole.Experimental
LomitapideThe serum concentration of Lomitapide can be increased when it is combined with Itraconazole.Approved, Investigational
LoperamideThe metabolism of Loperamide can be decreased when combined with Itraconazole.Approved
LopinavirThe serum concentration of Itraconazole can be increased when it is combined with Lopinavir.Approved
LoratadineThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Loratadine.Approved, Investigational
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Itraconazole.Approved
LorpiprazoleThe serum concentration of Itraconazole can be increased when it is combined with Lorpiprazole.Approved
LosartanThe metabolism of Losartan can be decreased when combined with Itraconazole.Approved
LoteprednolThe serum concentration of Loteprednol can be increased when it is combined with Itraconazole.Approved
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Itraconazole.Approved, Investigational
LuliconazoleThe serum concentration of Itraconazole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Itraconazole can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be increased when it is combined with Itraconazole.Approved
LurasidoneThe serum concentration of Lurasidone can be increased when it is combined with Itraconazole.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of adverse effects can be increased when Lysergic Acid Diethylamide is combined with Itraconazole.Illicit, Investigational, Withdrawn
MacimorelinThe metabolism of Macimorelin can be decreased when combined with Itraconazole.Approved, Investigational
MacitentanThe serum concentration of Macitentan can be increased when it is combined with Itraconazole.Approved
MagaldrateThe serum concentration of Itraconazole can be decreased when it is combined with Magaldrate.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium oxideThe serum concentration of Itraconazole can be decreased when it is combined with Magnesium oxide.Approved
Magnesium peroxideThe serum concentration of Itraconazole can be decreased when it is combined with Magnesium peroxide.Experimental
Magnesium silicateThe serum concentration of Itraconazole can be decreased when it is combined with Magnesium silicate.Approved
Magnesium sulfateThe metabolism of Magnesium sulfate can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ManidipineThe metabolism of Manidipine can be decreased when combined with Itraconazole.Approved, Investigational
MaravirocThe serum concentration of Maraviroc can be increased when it is combined with Itraconazole.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Itraconazole.Investigational
MebendazoleThe metabolism of Mebendazole can be decreased when combined with Itraconazole.Approved, Vet Approved
Medical CannabisThe metabolism of Medical Cannabis can be decreased when combined with Itraconazole.Experimental, Investigational
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be increased when it is combined with Itraconazole.Approved, Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Itraconazole.Approved
MefloquineThe metabolism of Mefloquine can be decreased when combined with Itraconazole.Approved, Investigational
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Itraconazole.Vet Approved
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Itraconazole.Approved, Vet Approved
MentholThe metabolism of Menthol can be decreased when combined with Itraconazole.Approved
MepyramineThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Mepyramine.Approved, Vet Approved
MetergolineThe risk or severity of adverse effects can be increased when Metergoline is combined with Itraconazole.Experimental
MethadoneThe serum concentration of Methadone can be increased when it is combined with Itraconazole.Approved
MethanthelineThe serum concentration of Itraconazole can be decreased when it is combined with Methantheline.Approved, Investigational
MethaqualoneThe metabolism of Methaqualone can be decreased when combined with Itraconazole.Illicit, Withdrawn
MethoxsalenThe metabolism of Methoxsalen can be decreased when combined with Itraconazole.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
MethsuximideThe therapeutic efficacy of Itraconazole can be increased when used in combination with Methsuximide.Approved
MethylergometrineThe serum concentration of Methylergometrine can be increased when it is combined with Itraconazole.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Itraconazole.Approved, Vet Approved
MethyltestosteroneThe metabolism of Methyltestosterone can be decreased when combined with Itraconazole.Approved
MethysergideThe risk or severity of adverse effects can be increased when Methysergide is combined with Itraconazole.Approved
MetiamideThe serum concentration of Itraconazole can be decreased when it is combined with Metiamide.Experimental
MetildigoxinThe serum concentration of Metildigoxin can be increased when it is combined with Itraconazole.Experimental
MetoclopramideThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Metoclopramide.Approved, Investigational
MetoprololThe risk or severity of hyperkalemia can be increased when Itraconazole is combined with Metoprolol.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Itraconazole.Approved
MevastatinThe serum concentration of Mevastatin can be increased when it is combined with Itraconazole.Experimental
MexiletineThe metabolism of Mexiletine can be decreased when combined with Itraconazole.Approved, Investigational
MianserinThe metabolism of Mianserin can be decreased when combined with Itraconazole.Approved, Investigational
MibefradilThe metabolism of Mibefradil can be decreased when combined with Itraconazole.Investigational, Withdrawn
MiconazoleThe metabolism of Miconazole can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Itraconazole.Approved, Illicit
MidecamycinThe metabolism of Midecamycin can be decreased when combined with Itraconazole.Approved
MidostaurinThe metabolism of Midostaurin can be decreased when combined with Itraconazole.Approved, Investigational
MifepristoneThe serum concentration of Itraconazole can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe metabolism of Mirabegron can be decreased when combined with Itraconazole.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Itraconazole.Approved
MitotaneThe serum concentration of Itraconazole can be decreased when it is combined with Mitotane.Approved
ModafinilThe metabolism of Modafinil can be decreased when combined with Itraconazole.Approved, Investigational
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Itraconazole.Approved, Vet Approved
MontelukastThe metabolism of Montelukast can be decreased when combined with Itraconazole.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Itraconazole.Approved, Investigational
MoxifloxacinThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe metabolism of Mycophenolate mofetil can be decreased when combined with Itraconazole.Approved, Investigational
NabiximolsThe metabolism of Nabiximols can be decreased when combined with Itraconazole.Approved, Investigational
NaftopidilThe metabolism of Naftopidil can be decreased when combined with Itraconazole.Investigational
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Itraconazole.Approved
NaloxoneThe metabolism of Naloxone can be decreased when combined with Itraconazole.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Itraconazole.Approved, Investigational
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Itraconazole.Investigational
NefazodoneThe metabolism of Itraconazole can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Itraconazole can be decreased when combined with Nelfinavir.Approved
NeratinibThe metabolism of Neratinib can be decreased when combined with Itraconazole.Approved, Investigational
NetupitantThe serum concentration of Itraconazole can be increased when it is combined with Netupitant.Approved, Investigational
NevirapineThe serum concentration of Itraconazole can be decreased when it is combined with Nevirapine.Approved
NicardipineThe metabolism of Nicardipine can be decreased when combined with Itraconazole.Approved, Investigational
NicergolineThe risk or severity of adverse effects can be increased when Nicergoline is combined with Itraconazole.Approved, Investigational
NicotineThe metabolism of Nicotine can be decreased when combined with Itraconazole.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Itraconazole.Approved
NiguldipineThe metabolism of Niguldipine can be decreased when combined with Itraconazole.Experimental
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Itraconazole.Approved, Investigational
NiludipineThe metabolism of Niludipine can be decreased when combined with Itraconazole.Experimental
NilvadipineThe metabolism of Nilvadipine can be decreased when combined with Itraconazole.Approved, Investigational
NimesulideThe metabolism of Nimesulide can be decreased when combined with Itraconazole.Approved, Investigational, Withdrawn
NimodipineThe serum concentration of Nimodipine can be increased when it is combined with Itraconazole.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Itraconazole.Approved
NiperotidineThe serum concentration of Itraconazole can be decreased when it is combined with Niperotidine.Experimental, Investigational
NisoldipineThe serum concentration of Nisoldipine can be increased when it is combined with Itraconazole.Approved
NitrazepamThe metabolism of Nitrazepam can be decreased when combined with Itraconazole.Approved
NitrendipineThe metabolism of Nitrendipine can be decreased when combined with Itraconazole.Approved, Investigational
NizatidineThe serum concentration of Itraconazole can be decreased when it is combined with Nizatidine.Approved
NorethisteroneThe metabolism of Norethisterone can be decreased when combined with Itraconazole.Approved
NorgestrelThe metabolism of Norgestrel can be decreased when combined with Itraconazole.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Itraconazole.Approved
NylidrinThe metabolism of Nylidrin can be decreased when combined with Itraconazole.Approved
OdanacatibThe metabolism of Odanacatib can be decreased when combined with Itraconazole.Investigational
OfloxacinItraconazole may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe serum concentration of Itraconazole can be decreased when it is combined with Olanzapine.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be increased when it is combined with Itraconazole.Approved
OleandrinThe serum concentration of Oleandrin can be increased when it is combined with Itraconazole.Experimental, Investigational
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Itraconazole.Investigational
OlopatadineThe metabolism of Olopatadine can be decreased when combined with Itraconazole.Approved
OmeprazoleOmeprazole can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
OndansetronThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Ondansetron.Approved
OpiumThe metabolism of Opium can be decreased when combined with Itraconazole.Approved, Illicit
OrphenadrineThe metabolism of Orphenadrine can be decreased when combined with Itraconazole.Approved
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Itraconazole.Approved
OspemifeneThe serum concentration of Ospemifene can be increased when it is combined with Itraconazole.Approved, Investigational
OtiloniumThe metabolism of Otilonium can be decreased when combined with Itraconazole.Experimental, Investigational
OuabainThe serum concentration of Ouabain can be increased when it is combined with Itraconazole.Approved
OxazepamThe metabolism of Oxazepam can be decreased when combined with Itraconazole.Approved
OxybutyninThe serum concentration of Oxybutynin can be increased when it is combined with Itraconazole.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Itraconazole is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
PaclitaxelThe metabolism of Paclitaxel can be decreased when combined with Itraconazole.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be increased when it is combined with Itraconazole.Approved, Investigational
PaliperidoneItraconazole may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Itraconazole.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Itraconazole.Approved, Investigational
PantoprazoleThe serum concentration of Itraconazole can be decreased when it is combined with Pantoprazole.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Itraconazole.Approved
ParamethasoneThe metabolism of Paramethasone can be decreased when combined with Itraconazole.Approved
ParecoxibThe serum concentration of Parecoxib can be increased when it is combined with Itraconazole.Approved
ParicalcitolThe serum concentration of Paricalcitol can be increased when it is combined with Itraconazole.Approved, Investigational
ParitaprevirThe metabolism of Paritaprevir can be decreased when combined with Itraconazole.Approved, Investigational
ParoxetineThe serum concentration of Itraconazole can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Itraconazole.Approved
PenfluridolThe metabolism of Penfluridol can be decreased when combined with Itraconazole.Experimental
PentamidineThe metabolism of Pentamidine can be decreased when combined with Itraconazole.Approved, Investigational
PentobarbitalThe serum concentration of Itraconazole can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerampanelThe metabolism of Perampanel can be decreased when combined with Itraconazole.Approved
PerflutrenItraconazole may increase the QTc-prolonging activities of Perflutren.Approved
PergolideThe risk or severity of adverse effects can be increased when Pergolide is combined with Itraconazole.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Itraconazole.Approved, Investigational
PermethrinThe metabolism of Permethrin can be decreased when combined with Itraconazole.Approved, Investigational
PerospironeThe metabolism of Perospirone can be decreased when combined with Itraconazole.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Itraconazole.Approved
PeruvosideThe serum concentration of Peruvoside can be increased when it is combined with Itraconazole.Experimental
PethidineThe metabolism of Pethidine can be decreased when combined with Itraconazole.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Itraconazole.Withdrawn
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Itraconazole.Approved, Investigational
PheniramineThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Pheniramine.Approved
PhenobarbitalThe serum concentration of Itraconazole can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be decreased when combined with Itraconazole.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Itraconazole.Approved, Investigational
PhenytoinThe serum concentration of Itraconazole can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe metabolism of Pilocarpine can be decreased when combined with Itraconazole.Approved, Investigational
PimecrolimusThe metabolism of Pimecrolimus can be decreased when combined with Itraconazole.Approved, Investigational
PimozideThe serum concentration of Pimozide can be increased when it is combined with Itraconazole.Approved
PinacidilThe metabolism of Pinacidil can be decreased when combined with Itraconazole.Approved
PinaveriumThe metabolism of Pinaverium can be decreased when combined with Itraconazole.Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Itraconazole.Approved, Investigational
PiperaquineThe metabolism of Piperaquine can be decreased when combined with Itraconazole.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Itraconazole.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Itraconazole.Approved
PitolisantThe serum concentration of Pitolisant can be increased when it is combined with Itraconazole.Approved, Investigational
PodofiloxThe metabolism of Podofilox can be decreased when combined with Itraconazole.Approved
PomalidomideThe metabolism of Pomalidomide can be decreased when combined with Itraconazole.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Itraconazole.Approved, Investigational
PosaconazoleThe metabolism of Posaconazole can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Itraconazole.Approved, Withdrawn
PranlukastThe serum concentration of Pranlukast can be increased when it is combined with Itraconazole.Approved, Investigational
PrasteroneThe metabolism of Prasterone can be decreased when combined with Itraconazole.Approved, Investigational, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Itraconazole.Investigational
PrasugrelThe serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Itraconazole resulting in a loss in efficacy.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Itraconazole.Approved
PrazepamThe metabolism of Prazepam can be decreased when combined with Itraconazole.Approved, Illicit
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Itraconazole.Approved, Investigational
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Itraconazole.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Itraconazole.Approved, Vet Approved
PregabalinThe metabolism of Pregabalin can be decreased when combined with Itraconazole.Approved, Illicit, Investigational
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Itraconazole.Approved, Experimental, Investigational
PrenylamineThe metabolism of Prenylamine can be decreased when combined with Itraconazole.Withdrawn
PrimaquineThe metabolism of Primaquine can be decreased when combined with Itraconazole.Approved
PrimidoneThe serum concentration of Itraconazole can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcainamideItraconazole may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Itraconazole.Approved, Vet Approved
ProgesteroneThe absorption of Progesterone can be decreased when combined with Itraconazole.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Itraconazole.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Itraconazole.Approved, Vet Approved
PromethazineThe serum concentration of Itraconazole can be increased when it is combined with Promethazine.Approved, Investigational
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Itraconazole.Approved
PropiverineThe metabolism of Propiverine can be decreased when combined with Itraconazole.Approved, Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Itraconazole.Approved, Investigational
ProscillaridinThe serum concentration of Proscillaridin can be increased when it is combined with Itraconazole.Experimental
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Itraconazole.Approved
PyrazinamideThe metabolism of Pyrazinamide can be decreased when combined with Itraconazole.Approved, Investigational
QuazepamThe metabolism of Quazepam can be decreased when combined with Itraconazole.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Itraconazole.Approved
QuinacrineThe metabolism of Quinacrine can be decreased when combined with Itraconazole.Approved, Investigational
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Itraconazole.Approved, Investigational
QuinineThe metabolism of Quinine can be decreased when combined with Itraconazole.Approved
RabeprazoleThe serum concentration of Itraconazole can be decreased when it is combined with Rabeprazole.Approved, Investigational
RaloxifeneThe metabolism of Raloxifene can be decreased when combined with Itraconazole.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be increased when it is combined with Itraconazole.Approved, Investigational
RanitidineRanitidine can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Itraconazole.Approved, Investigational
ReboxetineThe metabolism of Reboxetine can be decreased when combined with Itraconazole.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be increased when it is combined with Itraconazole.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Itraconazole.Approved, Investigational
RetapamulinThe serum concentration of Retapamulin can be increased when it is combined with Itraconazole.Approved
RibociclibThe serum concentration of Ribociclib can be increased when it is combined with Itraconazole.Approved, Investigational
RifabutinThe serum concentration of Itraconazole can be decreased when it is combined with Rifabutin.Approved, Investigational
RifampicinThe serum concentration of Itraconazole can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Itraconazole can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Itraconazole.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Itraconazole.Approved
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Itraconazole.Approved
RimonabantThe metabolism of Rimonabant can be decreased when combined with Itraconazole.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be increased when it is combined with Itraconazole.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Itraconazole.Approved, Investigational
RitonavirThe serum concentration of Itraconazole can be increased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe metabolism of Rivaroxaban can be decreased when combined with Itraconazole.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Itraconazole.Approved, Investigational, Withdrawn
RolapitantThe metabolism of Rolapitant can be decreased when combined with Itraconazole.Approved, Investigational
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Itraconazole.Approved, Investigational
RopiniroleThe metabolism of Ropinirole can be decreased when combined with Itraconazole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Itraconazole.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Itraconazole.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Itraconazole.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Itraconazole.Approved
Roxatidine acetateThe serum concentration of Itraconazole can be decreased when it is combined with Roxatidine acetate.Approved, Investigational
RoxithromycinThe metabolism of Roxithromycin can be decreased when combined with Itraconazole.Approved, Investigational, Withdrawn
RucaparibThe metabolism of Rucaparib can be decreased when combined with Itraconazole.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Itraconazole.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be increased when it is combined with Itraconazole.Approved
SafinamideThe metabolism of Safinamide can be decreased when combined with Itraconazole.Approved, Investigational
SalbutamolThe risk or severity of QTc prolongation can be increased when Salbutamol is combined with Itraconazole.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be increased when it is combined with Itraconazole.Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Itraconazole.Approved, Investigational
SarilumabThe therapeutic efficacy of Itraconazole can be decreased when used in combination with Sarilumab.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be increased when it is combined with Itraconazole.Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
SeletracetamThe metabolism of Seletracetam can be decreased when combined with Itraconazole.Investigational
SelexipagThe metabolism of Selexipag can be decreased when combined with Itraconazole.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Itraconazole.Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Itraconazole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Sertraline can be decreased when combined with Itraconazole.Approved
SevofluraneThe metabolism of Sevoflurane can be decreased when combined with Itraconazole.Approved, Vet Approved
SibutramineThe metabolism of Sibutramine can be decreased when combined with Itraconazole.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Itraconazole.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Itraconazole.Approved
SiltuximabThe serum concentration of Itraconazole can be decreased when it is combined with Siltuximab.Approved, Investigational
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Itraconazole.Approved
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Itraconazole.Approved
SirolimusThe serum concentration of Sirolimus can be increased when it is combined with Itraconazole.Approved, Investigational
SitagliptinThe metabolism of Sitagliptin can be decreased when combined with Itraconazole.Approved, Investigational
Sodium bicarbonateThe serum concentration of Itraconazole can be decreased when it is combined with Sodium bicarbonate.Approved
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Itraconazole.Approved
SonidegibThe serum concentration of Sonidegib can be increased when it is combined with Itraconazole.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Itraconazole.Approved, Investigational
SotalolItraconazole may increase the QTc-prolonging activities of Sotalol.Approved
SpiramycinThe metabolism of Spiramycin can be decreased when combined with Itraconazole.Approved
SpironolactoneThe risk or severity of hyperkalemia can be increased when Spironolactone is combined with Itraconazole.Approved
St. John's WortThe serum concentration of Itraconazole can be decreased when it is combined with St. John's Wort.Approved, Investigational, Nutraceutical
StiripentolThe serum concentration of Itraconazole can be increased when it is combined with Stiripentol.Approved
SucralfateSucralfate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SufentanilThe metabolism of Sufentanil can be decreased when combined with Itraconazole.Approved, Investigational
SulfadiazineThe metabolism of Sulfadiazine can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Itraconazole.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Itraconazole.Approved
SulfisoxazoleThe metabolism of Itraconazole can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Sumatriptan can be increased when it is combined with Itraconazole.Approved, Investigational
SunitinibThe metabolism of Sunitinib can be decreased when combined with Itraconazole.Approved, Investigational
SuvorexantThe serum concentration of Suvorexant can be increased when it is combined with Itraconazole.Approved, Investigational
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Itraconazole.Approved
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Itraconazole.Approved
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Itraconazole.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be increased when it is combined with Itraconazole.Approved, Investigational
TamoxifenThe metabolism of Tamoxifen can be decreased when combined with Itraconazole.Approved
TamsulosinThe serum concentration of Tamsulosin can be increased when it is combined with Itraconazole.Approved, Investigational
TasimelteonThe serum concentration of Tasimelteon can be increased when it is combined with Itraconazole.Approved, Investigational
TasosartanThe metabolism of Tasosartan can be decreased when combined with Itraconazole.Approved
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be decreased when combined with Itraconazole.Experimental
TelaprevirThe serum concentration of Itraconazole can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelavancinItraconazole may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe serum concentration of Telithromycin can be increased when it is combined with Itraconazole.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Itraconazole.Approved, Investigational
TemsirolimusThe serum concentration of the active metabolites of Temsirolimus can be increased when Temsirolimus is used in combination with Itraconazole.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Itraconazole.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be increased when it is combined with Itraconazole.Approved, Withdrawn
TergurideThe risk or severity of adverse effects can be increased when Terguride is combined with Itraconazole.Experimental
TerodilineThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Terodiline.Experimental
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Itraconazole.Investigational
TestosteroneThe metabolism of Testosterone can be decreased when combined with Itraconazole.Approved, Investigational
Testosterone cypionateThe metabolism of Testosterone cypionate can be decreased when combined with Itraconazole.Approved
Testosterone enanthateThe metabolism of Testosterone enanthate can be decreased when combined with Itraconazole.Approved
Testosterone propionateThe metabolism of Testosterone propionate can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved, Withdrawn
Testosterone undecanoateThe metabolism of Testosterone undecanoate can be decreased when combined with Itraconazole.Approved, Investigational
TetrabenazineItraconazole may increase the QTc-prolonging activities of Tetrabenazine.Approved, Investigational
TetracyclineThe metabolism of Tetracycline can be decreased when combined with Itraconazole.Approved, Vet Approved
TetrahydropalmatineThe metabolism of Tetrahydropalmatine can be decreased when combined with Itraconazole.Investigational
TetrandrineThe metabolism of Tetrandrine can be decreased when combined with Itraconazole.Experimental
TezacaftorThe serum concentration of Tezacaftor can be increased when it is combined with Itraconazole.Approved, Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Itraconazole.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Itraconazole.Approved, Withdrawn
ThiotepaThe metabolism of Thiotepa can be decreased when combined with Itraconazole.Approved, Investigational
TiagabineThe metabolism of Tiagabine can be decreased when combined with Itraconazole.Approved, Investigational
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Itraconazole resulting in a loss in efficacy.Approved
TiclopidineThe metabolism of Ticlopidine can be decreased when combined with Itraconazole.Approved
TinidazoleThe metabolism of Tinidazole can be decreased when combined with Itraconazole.Approved, Investigational
TioclomarolThe serum concentration of Tioclomarol can be increased when it is combined with Itraconazole.Experimental
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Itraconazole.Approved
TipranavirThe serum concentration of Itraconazole can be increased when it is combined with Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Itraconazole.Approved, Withdrawn
TocilizumabThe serum concentration of Itraconazole can be decreased when it is combined with Tocilizumab.Approved
TocofersolanThe metabolism of Tocofersolan can be decreased when combined with Itraconazole.Approved
TocopherolThe metabolism of Tocopherol can be decreased when combined with Itraconazole.Approved, Investigational
TofacitinibThe serum concentration of Tofacitinib can be increased when it is combined with Itraconazole.Approved, Investigational
Tolfenamic AcidThe metabolism of Tolfenamic Acid can be decreased when combined with Itraconazole.Approved, Investigational
TolterodineThe serum concentration of Tolterodine can be increased when it is combined with Itraconazole.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Itraconazole.Approved
TopiramateThe serum concentration of Topiramate can be increased when it is combined with Itraconazole.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Itraconazole.Approved, Investigational
ToremifeneThe risk or severity of adverse effects can be increased when Itraconazole is combined with Toremifene.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be increased when it is combined with Itraconazole.Approved, Investigational
TramadolThe serum concentration of Tramadol can be increased when it is combined with Itraconazole.Approved, Investigational
TranilastThe metabolism of Tranilast can be decreased when combined with Itraconazole.Approved, Investigational
Trastuzumab emtansineThe serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Itraconazole.Approved, Investigational
TrazodoneThe metabolism of Trazodone can be decreased when combined with Itraconazole.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Itraconazole.Approved, Investigational, Nutraceutical
TriamcinoloneThe metabolism of Triamcinolone can be decreased when combined with Itraconazole.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Itraconazole.Approved, Investigational
TrimebutineThe metabolism of Trimebutine can be decreased when combined with Itraconazole.Approved
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Itraconazole.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Itraconazole.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Itraconazole.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Itraconazole.Investigational, Withdrawn
TroleandomycinThe metabolism of Troleandomycin can be decreased when combined with Itraconazole.Approved
TromethamineThe serum concentration of Itraconazole can be decreased when it is combined with Tromethamine.Approved
UdenafilThe metabolism of Udenafil can be decreased when combined with Itraconazole.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Itraconazole.Approved
UlobetasolThe serum concentration of Ulobetasol can be increased when it is combined with Itraconazole.Approved
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Itraconazole.Approved, Investigational
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Itraconazole.Approved, Investigational, Withdrawn
Valproic AcidThe risk or severity of QTc prolongation can be increased when Itraconazole is combined with Valproic Acid.Approved, Investigational
VandetanibThe metabolism of Vandetanib can be decreased when combined with Itraconazole.Approved
VanoxerineThe metabolism of Vanoxerine can be decreased when combined with Itraconazole.Investigational
VardenafilThe serum concentration of Vardenafil can be increased when it is combined with Itraconazole.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Itraconazole.Approved
VelpatasvirThe metabolism of Velpatasvir can be decreased when combined with Itraconazole.Approved, Investigational
VemurafenibThe risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Itraconazole.Approved
VenetoclaxThe metabolism of Venetoclax can be decreased when combined with Itraconazole.Approved, Investigational
VenlafaxineThe metabolism of Venlafaxine can be decreased when combined with Itraconazole.Approved
VerapamilThe metabolism of Verapamil can be decreased when combined with Itraconazole.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Itraconazole.Investigational
VilanterolThe metabolism of Vilanterol can be decreased when combined with Itraconazole.Approved
VilazodoneThe serum concentration of Vilazodone can be increased when it is combined with Itraconazole.Approved
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Itraconazole.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Itraconazole.Approved, Investigational
VincristineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Vincristine.Approved, Investigational
VindesineThe serum concentration of Vindesine can be increased when it is combined with Itraconazole.Approved, Investigational
VinflunineThe metabolism of Vinflunine can be decreased when combined with Itraconazole.Approved, Investigational
VinorelbineThe risk or severity of adverse effects can be increased when Itraconazole is combined with Vinorelbine.Approved, Investigational
VinpocetineThe metabolism of Vinpocetine can be decreased when combined with Itraconazole.Investigational
VismodegibThe metabolism of Vismodegib can be decreased when combined with Itraconazole.Approved, Investigational
VorapaxarThe serum concentration of Vorapaxar can be increased when it is combined with Itraconazole.Approved
VoriconazoleThe metabolism of Itraconazole can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Itraconazole.Approved, Investigational
VoxilaprevirThe metabolism of Voxilaprevir can be decreased when combined with Itraconazole.Approved, Investigational
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Itraconazole.Approved
WIN 55212-2The metabolism of WIN 55212-2 can be decreased when combined with Itraconazole.Experimental
YohimbineThe metabolism of Yohimbine can be decreased when combined with Itraconazole.Approved, Investigational, Vet Approved
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Itraconazole.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Itraconazole.Approved, Investigational
ZaleplonThe metabolism of Zaleplon can be decreased when combined with Itraconazole.Approved, Illicit, Investigational
ZiconotideThe metabolism of Ziconotide can be decreased when combined with Itraconazole.Approved
ZidovudineThe metabolism of Zidovudine can be decreased when combined with Itraconazole.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Itraconazole.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Ziprasidone can be decreased when combined with Itraconazole.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Itraconazole.Approved
ZomepiracThe metabolism of Zomepirac can be decreased when combined with Itraconazole.Withdrawn
ZonisamideThe metabolism of Zonisamide can be decreased when combined with Itraconazole.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be increased when it is combined with Itraconazole.Approved
ZotepineThe metabolism of Zotepine can be decreased when combined with Itraconazole.Approved, Investigational, Withdrawn
ZuclopenthixolThe serum concentration of Zuclopenthixol can be increased when it is combined with Itraconazole.Approved, Investigational
Food Interactions
  • Avoid milk, calcium containing dairy products, iron, antacids, or aluminum salts 2 hours before or 6 hours after using antacids while on this medication.
  • Avoid taking with grapefruit juice.
  • Take after a full meal.
  • Take with food.

References

Synthesis Reference

Jong-Soo Woo, Hong-Gi Yi, "Antifungal oral composition containing itraconazole and process for preparing same." U.S. Patent US6039981, issued May, 1998.

US6039981
General References
Not Available
External Links
Human Metabolome Database
HMDB0015298
KEGG Drug
D00350
PubChem Compound
55283
PubChem Substance
46505954
ChemSpider
49927
BindingDB
50127138
ChEBI
6076
ChEMBL
CHEMBL22587
Therapeutic Targets Database
DAP000631
PharmGKB
PA450132
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Itraconazole
ATC Codes
J02AC02 — Itraconazole
AHFS Codes
  • 08:14.08 — Azoles
FDA label
Download (1.58 MB)
MSDS
Download (73.6 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0Active Not RecruitingTreatmentSkin Basal Cell Carcinoma1
0RecruitingBasic SciencePharmacokinetics1
0RecruitingOtherEsophageal Cancers1
0RecruitingTreatmentBasal Cell Carcinoma (BCC)1
0RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1Active Not RecruitingBasic ScienceAdvanced Solid Tumors / Relapsed/Refractory Lymphoma1
1Active Not RecruitingOtherAdvanced (Inoperable) Non Small Cell Lung Cancer / Advanced Non Small Cell Lung Cancer1
1Active Not RecruitingOtherOncology, Medical1
1Active Not RecruitingTreatmentGlioblastomas1
1Active Not RecruitingTreatmentMetastatic Melanoma, BRAF V600 Mutation Positive1
1Active Not RecruitingTreatmentNeoplasms1
1Active Not RecruitingTreatmentOncology, Medical1
1CompletedNot AvailableCandidiasis infection / Dermatomycoses / Fungal infection of the dermal / Histoplasmosis1
1CompletedNot AvailableDrug-Drug Interaction (DDI) / Healthy Volunteers / Pharmacokinetics1
1CompletedNot AvailableHealthy Participants / Healthy Volunteers1
1CompletedNot AvailableHealthy Volunteers4
1CompletedNot AvailableHealthy Volunteers / Hepatic Insufficiency / Renal Insufficiency,Chronic1
1CompletedNot AvailableOncology, Medical1
1CompletedNot AvailableTumors, Solid1
1CompletedBasic ScienceAlzheimer's Disease (AD) / Healthy Volunteers1
1CompletedBasic ScienceClinical Trials, Phase I as Topic1
1CompletedBasic ScienceDDI (Drug-Drug Interaction) / Healthy Volunteers / Pharmacokinetics1
1CompletedBasic ScienceHealthy Participants2
1CompletedBasic ScienceHealthy Volunteers11
1CompletedBasic ScienceHealthy Volunteers: Asian, Non-Asian1
1CompletedBasic ScienceHealthy Volunteers / Pharmacokinetics of ASP37001
1CompletedBasic ScienceThrombosis2
1CompletedBasic ScienceTumors, Solid1
1CompletedOtherBiological Availability1
1CompletedOtherDrug Interaction Potentiation / Healthy Volunteers1
1CompletedOtherHealthy Participants2
1CompletedOtherHealthy Volunteers3
1CompletedOtherHealthy Volunteers / Non-Smokers1
1CompletedOtherMalignancies Multiple1
1CompletedTreatmentAdvanced Solid Tumors2
1CompletedTreatmentAsthma Bronchial1
1CompletedTreatmentBacterial Infections1
1CompletedTreatmentCachexia1
1CompletedTreatmentCystic Fibrosis (CF)1
1CompletedTreatmentDrug Drug Interaction (DDI)1
1CompletedTreatmentDrug Interactions2
1CompletedTreatmentHealthy Participants2
1CompletedTreatmentHealthy Patient Study1
1CompletedTreatmentHealthy Volunteers22
1CompletedTreatmentHistoplasmosis / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentJapanese Healthy Adult Males1
1CompletedTreatmentNeoplasms1
1CompletedTreatmentNocturia1
1CompletedTreatmentPain, Neuropathic1
1CompletedTreatmentPediatric, Cancer1
1CompletedTreatmentPharmacokinetics3
1CompletedTreatmentPulmonary Disease, Chronic Obstructive1
1CompletedTreatmentRelapsed Multiple Myeloma1
1CompletedTreatmentSinusitis1
1CompletedTreatmentSpinal Muscular Atrophy (SMA)1
1Not Yet RecruitingBasic ScienceInflammatory Bowel Diseases (IBD)1
1Not Yet RecruitingTreatmentPharmacokinetic Study in Healthy Male Volunteers1
1RecruitingBasic ScienceAutoimmune Diseases / Drug Drug Interactions / Fibrotic Disease1
1RecruitingBasic ScienceHealthy Volunteers2
1RecruitingOtherHealthy Volunteers2
1RecruitingTreatmentAdvanced Malignancies (Except Leukemia) / Advanced Malignancies Except Leukemia / Non-Small Cell Lung Cancer (ALK-positive) / Non-Small Cell Lung Cancer (c-Met Dependent) / Non-Small Cell Lung Cancer (ROS Marker Positive) / Non-Small Cell Lung Cancer ALK-positive / Non-Small Cell Lung Cancer c-Met Dependent / Non-Small Cell Lung Cancer ROS Marker Positive / Systemic Anaplastic Large-Cell Lymphoma1
1RecruitingTreatmentCytochrome P450 Interaction1
1RecruitingTreatmentNeoplasms Metastasis1
1TerminatedBasic SciencePolycystic Ovaries Syndrome1
1WithdrawnTreatmentAlzheimer's Disease (AD)1
1WithdrawnTreatmentHealthy Volunteers1
1, 2CompletedTreatmentBlastomycosis / Histoplasmosis / Sporotrichosis1
1, 2CompletedTreatmentChronic Hepatitis C Virus (HCV) Infection1
1, 2CompletedTreatmentLeukemia Acute Myeloid Leukemia (AML) / Myelodysplastic Syndromes1
1, 2RecruitingTreatmentPlatinum-resistant Epithelial Ovarian Cancer1
1, 2WithdrawnTreatmentCastration-Resistant Prostate Cancer (CRPC) / Prostate Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma, Prostate / Prostate Cancer / Recurrent Prostate Carcinoma / Stage I Prostate Adenocarcinoma AJCC v7 / Stage II Prostate Adenocarcinoma AJCC v7 / Stage III Prostate Adenocarcinoma AJCC v71
2CompletedTreatmentAspergillosis / Lung Diseases, Fungal1
2CompletedTreatmentBasal Cell Carcinoma (BCC) / Skin Cancers1
2CompletedTreatmentCystic Fibrosis (CF) / Prophylaxis of Aspergillus infection1
2CompletedTreatmentHematological Diseases / Neutropenia, Febrile1
2CompletedTreatmentHistoplasmosis / Human Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Meningitis, Cryptococcal1
2CompletedTreatmentMycoses1
2CompletedTreatmentOnychomycosis1
2CompletedTreatmentProstate Cancer1
2Not Yet RecruitingPreventionNeutropenias1
2Not Yet RecruitingTreatmentMycetoma1
2Not Yet RecruitingTreatmentTinea infections1
2TerminatedTreatmentAndrogen-insensitive Prostate Cancer / Castrate-resistant Prostate Cancer (CRPC) / Hormone-Refractory Prostate Cancer / Metastatic Disease / Prostate Cancer / Prostatic Neoplasms1
2TerminatedTreatmentRecurrent Non Small Cell Lung Cancer1
2Unknown StatusPreventionAllogeneic Stem Cell Transplantation / Hematological Diseases1
2, 3CompletedTreatmentAspergillosis, Allergic Bronchopulmonary1
2, 3CompletedTreatmentMinor burns1
2, 3Not Yet RecruitingTreatmentInfections, Fungal1
2, 3RecruitingTreatmentAspergillosis, Allergic Bronchopulmonary1
2, 3RecruitingTreatmentChronic Rhinosinusitis1
2, 3RecruitingTreatmentMinor burns1
3CompletedPreventionAntifungal Prophylaxis of Invasive Fungal Infections1
3CompletedPreventionFungaemia / Infections, Fungal1
3CompletedSupportive CareCancers1
3CompletedTreatmentBlastomycosis / Histoplasmosis / Human Immunodeficiency Virus (HIV) Infections1
3CompletedTreatmentOnychomycosis / Onychomycosis, Toenail Onychomychosis, Toenail Fungus1
3Not Yet RecruitingTreatmentAntifungal Drugs in Onychomycosis1
3Not Yet RecruitingTreatmentOvarian Carcinoma / Signal Transduction Pathway Deregulation / Therapy-Associated Cancer1
4CompletedNot AvailableFevers / Neoplasms, Hematologic / Neutropenias1
4CompletedNot AvailableNeutropenias1
4CompletedBasic SciencePharmacodynamics / Pharmacokinetics1
4CompletedPreventionCystic Fibrosis (CF)1
4CompletedPreventionInvasive Fungal Infections1
4CompletedPreventionMycoses / Neoplasms, Brain / Neuroblastomas / Retinoblastoma / Wilms' tumor1
4CompletedTreatmentChronic Cavitary Pulmonary Aspergillosis1
4CompletedTreatmentNeoplasms, Hematologic1
4CompletedTreatmentOnychomycosis, Toe1
4CompletedTreatmentPulmonary Fungal Infection1
4Not Yet RecruitingBasic ScienceHealthy Volunteers1
4RecruitingNot AvailableNeutropenias / Systemic Mycosis1
4TerminatedPreventionGraft Versus Host Disease (GVHD)1
4TerminatedTreatmentAspergillosis, Allergic Bronchopulmonary / Cystic Fibrosis (CF)1
Not AvailableActive Not RecruitingNot AvailableSystemic Fungal Infections1
Not AvailableCompletedSupportive CareCancers1
Not AvailableCompletedTreatmentEsophageal Candidiasis / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHistoplasmosis / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Meningitis, Cryptococcal1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Oral Candidiasis2
Not AvailableCompletedTreatmentNeoplasms Metastasis / Neoplasms, Breast1
Not AvailableCompletedTreatmentVulvovaginal Candidiasis1
Not AvailableNot Yet RecruitingTreatmentSkin Basal Cell Carcinoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Advanced Pharmaceutical Services Inc.
  • AQ Pharmaceuticals Inc.
  • Centocor Ortho Biotech Inc.
  • Eon Labs
  • Hospira Inc.
  • Janssen-Ortho Inc.
  • Medisca Inc.
  • Murfreesboro Pharmaceutical Nursing Supply
  • Ortho Mcneil Janssen Pharmaceutical Inc.
  • Patriot Pharmaceuticals
  • Physicians Total Care Inc.
  • Resource Optimization and Innovation LLC
Dosage forms
FormRouteStrength
Capsule, coated pelletsOral100 mg/1
SolutionOral10 mg/mL
TabletOral200 mg/1
CapsuleOral100 mg/1
CapsuleOral100 mg
SolutionOral10 mg
Prices
Unit descriptionCostUnit
Itraconazole 28 100 mg capsule Disp Pack270.89USD disp
Itraconazole powder32.13USD g
Sporanox 100 mg capsule12.14USD capsule
Itraconazole 100 mg capsule9.46USD capsule
Sporanox 10 mg/ml Solution1.41USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5633015No1994-05-272014-05-27Us
CA2142848No1999-11-162013-08-27Canada
CA1336498No1995-08-012012-08-01Canada
US6407079No1999-06-182019-06-18Us
US6509038No1997-05-122017-05-12Us
US7081255No1997-05-122017-05-12Us
US8486456No2008-10-032028-10-03Us
US8591948No1997-05-122017-05-12Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)166.2 °CNot Available
water solubilityInsolubleNot Available
logP5.66HTTP://WWW.RXLIST.COM
pKa3.70Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00964 mg/mLALOGPS
logP5.48ALOGPS
logP7.31ChemAxon
logS-4.9ALOGPS
pKa (Strongest Basic)3.92ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area100.79 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity200.4 m3·mol-1ChemAxon
Polarizability74.7 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9973
Blood Brain Barrier-0.6151
Caco-2 permeable+0.5511
P-glycoprotein substrateSubstrate0.6397
P-glycoprotein inhibitor IInhibitor0.7973
P-glycoprotein inhibitor IINon-inhibitor0.88
Renal organic cation transporterNon-inhibitor0.7497
CYP450 2C9 substrateNon-substrate0.8116
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateNon-inhibitor0.7666
CYP450 2C9 inhibitorInhibitor0.618
CYP450 2D6 inhibitorNon-inhibitor0.8622
CYP450 2C19 inhibitorInhibitor0.5703
CYP450 3A4 inhibitorInhibitor0.5279
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.8219
Ames testAMES toxic0.5303
CarcinogenicityNon-carcinogens0.7478
BiodegradationNot ready biodegradable1.0
Rat acute toxicity3.3118 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5782
hERG inhibition (predictor II)Inhibitor0.6096
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0329000000-18fc35342fd0b509b439
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0112100900-c45b863fbc00a8c449b4

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazinanes
Sub Class
Piperazines
Direct Parent
Phenylpiperazines
Alternative Parents
N-arylpiperazines / Phenyl-1,2,4-triazoles / Aminophenyl ethers / Phenoxy compounds / Aniline and substituted anilines / Dichlorobenzenes / Dialkylarylamines / Alkyl aryl ethers / Ketals / Aryl chlorides
show 8 more
Substituents
Phenylpiperazine / N-arylpiperazine / Phenyltriazole / Phenyl-1,2,4-triazole / Aminophenyl ether / Phenol ether / Phenoxy compound / Tertiary aliphatic/aromatic amine / 1,3-dichlorobenzene / Dialkylarylamine
show 30 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
N-arylpiperazine, triazole antifungal drug, conazole antifungal drug, dioxolane, dichlorobenzene, triazoles, cyclic ketal (CHEBI:6076)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sterol 14-demethylase activity
Specific Function
Catalyzes C14-demethylation of lanosterol; it transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol.
Gene Name
CYP51A1
Uniprot ID
Q16850
Uniprot Name
Lanosterol 14-alpha demethylase
Molecular Weight
56805.26 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Cotrim PC, Garrity LK, Beverley SM: Isolation of genes mediating resistance to inhibitors of nucleoside and ergosterol metabolism in Leishmania by overexpression/selection. J Biol Chem. 1999 Dec 31;274(53):37723-30. [PubMed:10608831]
  3. Carrillo-Munoz AJ, Giusiano G, Ezkurra PA, Quindos G: Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9. [PubMed:16964330]
Kind
Protein
Organism
Yeast
Pharmacological action
Yes
Actions
Inhibitor
General Function
Sterol 14-demethylase activity
Specific Function
Catalyzes C14-demethylation of lanosterol which is critical for ergosterol biosynthesis. It transforms lanosterol into 4,4'-dimethyl cholesta-8,14,24-triene-3-beta-ol (By similarity).
Gene Name
ERG11
Uniprot ID
P50859
Uniprot Name
Lanosterol 14-alpha demethylase
Molecular Weight
61304.95 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Gachotte D, Pierson CA, Lees ND, Barbuch R, Koegel C, Bard M: A yeast sterol auxotroph (erg25) is rescued by addition of azole antifungals and reduced levels of heme. Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11173-8. [PubMed:9326581]
  4. Henry KW, Nickels JT, Edlind TD: Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors. Antimicrob Agents Chemother. 2000 Oct;44(10):2693-700. [PubMed:10991846]
  5. Morales IJ, Vohra PK, Puri V, Kottom TJ, Limper AH, Thomas CF Jr: Characterization of a lanosterol 14 alpha-demethylase from Pneumocystis carinii. Am J Respir Cell Mol Biol. 2003 Aug;29(2):232-8. Epub 2003 Feb 26. [PubMed:12606318]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  2. Flockhart Table - Indiana University [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  2. Flockhart Table - Indiana University [Link]
Details
3. Cytochrome P450 3A4
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Niwa T, Shiraga T, Takagi A: Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005 Sep;28(9):1805-8. [PubMed:16141567]
  2. Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin JS, Nakamura T, Nishiguchi K, Okamura N, Okumura K: Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol. 2005 Jun;57(6):759-64. [PubMed:15969931]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  4. Dresser GK, Spence JD, Bailey DG: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000 Jan;38(1):41-57. [PubMed:10668858]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
  6. Link [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Walsky RL, Astuccio AV, Obach RS: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 Dec;46(12):1426-38. [PubMed:17101742]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d 24-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A1
Uniprot ID
P04798
Uniprot Name
Cytochrome P450 1A1
Molecular Weight
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Wang EJ, Casciano CN, Clement RP, Johnson WW: Active transport of fluorescent P-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem Biophys Res Commun. 2001 Nov 30;289(2):580-5. [PubMed:11716514]
  2. Wang EJ, Lew K, Casciano CN, Clement RP, Johnson WW: Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother. 2002 Jan;46(1):160-5. [PubMed:11751127]
  3. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389]
  4. Takara K, Tanigawara Y, Komada F, Nishiguchi K, Sakaeda T, Okumura K: Cellular pharmacokinetic aspects of reversal effect of itraconazole on P-glycoprotein-mediated resistance of anticancer drugs. Biol Pharm Bull. 1999 Dec;22(12):1355-9. [PubMed:10746169]
  5. Masuda S, Inui K: [Molecular mechanisms on drug transporters in the drug absorption and disposition]. Nihon Rinsho. 2002 Jan;60(1):65-73. [PubMed:11808341]
  6. Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ: Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther. 2003 Mar;73(3):192-8. [PubMed:12621384]
  7. Sakaeda T, Iwaki K, Kakumoto M, Nishikawa M, Niwa T, Jin JS, Nakamura T, Nishiguchi K, Okamura N, Okumura K: Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol. 2005 Jun;57(6):759-64. [PubMed:15969931]
  8. Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R: Comparison of information on the pharmacokinetic interactions of Ca antagonists in the package inserts from three countries (Japan, USA and UK). Eur J Clin Pharmacol. 2005 Aug;61(7):531-6. Epub 2005 Jul 23. [PubMed:16041596]
  9. Shon JH, Yoon YR, Hong WS, Nguyen PM, Lee SS, Choi YG, Cha IJ, Shin JG: Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. Clin Pharmacol Ther. 2005 Aug;78(2):191-201. [PubMed:16084853]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P: Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15. [PubMed:22541068]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:49